July 10th 2025
Discover the serious health risks of smoking while pregnant, how vaping compares, and the most effective ways clinicians can help women quit.
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings
View More
Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine
View More
Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine
View More
Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Lead Investigator Perspectives on the Future of VMS Management
July 4th 2025A panelist emphasizes that the OASIS 4 findings, with those of prior OASIS studies, strongly support the use of this drug class for managing vasomotor symptoms (VMS) in patients with breast cancer receiving endocrine therapy and highlights the need for future research in underserved populations such as men with breast cancer and those with metastatic disease.
Hepatic Concerns: What OB/GYNs Should Know From OASIS 4
July 4th 2025A panelist explains that although liver function was closely monitored due to potential concerns about the investigational therapy and concurrent endocrine treatments, no serious hepatotoxicity was observed during the trial. However, continued monitoring in longer-term and real-world settings remains important to confirm the treatment’s liver safety profile.
Lead Investigator Reviews Early Safety Signals from Novel VMS Agents
July 4th 2025A panelist notes that although the treatment was generally well tolerated—with fatigue, somnolence, and diarrhea being the most common adverse effects—long-term data on breast cancer outcomes such as recurrence and survival are still lacking, underscoring the need for extended follow-up and real-world evidence to fully assess long-term safety and efficacy.
Improving Patient Tolerability: Elinzanetant in Breast Cancer Care
June 27th 2025A panelist emphasizes that effectively managing endocrine therapy adverse effects—particularly vasomotor symptoms—can significantly improve treatment adherence, which is critical for reducing recurrence risk and improving survival in patients with breast cancer.
Rapid Relief: Quality-of-Life Improvements Observed in Recent VMS Trials
June 27th 2025A panelist shares that secondary results from the trial showed early and sustained improvements in sleep and quality of life, underscoring the therapy’s potential to enhance endocrine treatment adherence by alleviating vasomotor symptoms (VMS) that often lead to poor adherence in patients with breast cancer.